Continuous Bioprocessing Market by Product (Bioreactors, Cell Culture Media & Reagent, Centrifuges), Process (Downstream Bioprocess, Upstream Bioprocess), Application, Scale of Operation, End-User - Global Forecast 2024-2030

Continuous Bioprocessing Market by Product (Bioreactors, Cell Culture Media & Reagent, Centrifuges), Process (Downstream Bioprocess, Upstream Bioprocess), Application, Scale of Operation, End-User - Global Forecast 2024-2030

The Continuous Bioprocessing Market size was estimated at USD 233.44 million in 2023 and expected to reach USD 282.42 million in 2024, at a CAGR 21.30% to reach USD 902.23 million by 2030.

Continuous bioprocessing represents a paradigm shift in the production of biopharmaceutical products, such as vaccines, monoclonal antibodies, or therapeutic proteins. Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.

Regional Insights

In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Continuous Bioprocessing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Growing demand for biopharmaceuticals & government support for the industry
Increased benefits over batch processing & uptake of single-use technology
Advent of industry 4.0 & trend towards automation & digitization

Market Restraints

Strict regulations for continuous bioprocessing coupled with high equipment cost

Market Opportunities

Adoption of perfusion associated with single-use equipment
Development of a continuous bioprocessing approach to stromal cell manufacturing

Market Challenges

Issues with operational difficulties and process changes

Market Segmentation Analysis

Product: Growing preference for bioreactors in large-scale production of recombinant proteins
Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Continuous Bioprocessing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale

WuXi Biologics announced that it has accomplished end-to-end DS manufacturing at a pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform. This well-configured bioprocess is being scaled up to GMP manufacturing and is going to be deployed across WuXi Biologics' global manufacturing sites in China, Ireland, the U.S., and Singapore.

Sartorius and Repligen Launch Integrated Bioreactor System

Sartorius and Repligen launched an integrated bioreactor system incorporating Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor. According to both companies, the goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology

3M company announced an investment of USD 146 million to expand its capabilities to support biotech manufacturing. This investment is going to accelerate 3M's development and delivery of vital filtration equipment developed for biological, bioprocessing, and small molecule pharmaceutical manufacturing applications, which enable biotech customers to continue to innovate therapies used for the treatment of conditions including multiple sclerosis, rheumatoid arthritis, and certain cancers.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Continuous Bioprocessing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kühner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Técnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Bioreactors
Cell Culture Media & Reagent
Centrifuges
Chromatography System
Filtration Systems
Incubators & Shakers
Process
Downstream Bioprocess
Upstream Bioprocess
Application
Cell & Gene Therapy
Monoclonal Antibodies
Vaccines
Scale of Operation
Clinical Operations
Commercial Operations
End-User
Academic & Research Institutes
Contract Development & Manufacturing Organizations
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year